<DOC>
	<DOCNO>NCT01262274</DOCNO>
	<brief_summary>The Aim study validate treatment anastrozole combination tegafur-uracil pre-operative therapy postmenopausal primary breast cancer . Although pre-operative hormone therapy novel therapeutic approach , hormone therapy limitation term efficacy . Metronomic chemotherapy , frequent administration low-dose cytotoxic agent , target tumor cell also inhibit angiogenesis . Because report efficacy hormone therapy add metronomic chemotherapy pre-operative therapy , randomize phase II trial anastrozole ( ANA ) combination with/without metronomic tegafur-uracil ( UFT ) neo-adjuvant postmenopausal breast cancer conduct .</brief_summary>
	<brief_title>Randomized Phase II Trial Anastrozole Plus Metronomic Tegafur-uracil Neo-adjuvant Therapy Postmenopausal Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>Histologicallyconfirmed diagnosis invasive breast cancer Clinical stage T2 , N0 N1 , M0 ( TNM Classification ) Patients must postmenopausal Tumors estrogen receptor ( ER ) positive human epidermal growth factor receptor ( HER2 ) negative ECOG Performance status ( PS ) 0 1 Patients must able swallow tablet capsule Candidates mastectomy breastconserving surgery Adequate bone marrow , liver renal function Written inform consent obtain patient randomization . Inoperable , bilateral inflammatory breast cancer multiple carcinoma Personal history invasive carcinoma Patients receive systemic therapy corticosteroid Patients receive estrogen preparation raloxifene Patients concurrent severe and/or uncontrolled medical disease Patients doctor judge inadequate enrollment study reason .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>